These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 28159782)

  • 21. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.
    Johansson S; Leonsson-Zachrisson M; Knutsson M; Spencer AG; Labonté ED; Deshpande D; Kohler J; Kozuka K; Charmot D; Rosenbaum DP
    Clin Pharmacol Drug Dev; 2017 Sep; 6(5):448-456. PubMed ID: 27654985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tenapanor: First Approval.
    Markham A
    Drugs; 2019 Nov; 79(17):1897-1903. PubMed ID: 31677150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients with Kidney Failure.
    Hill Gallant KM; Sprague SM; Rosenbaum DP; Spiegel DM; Kozuka K; Edelstein S; Chertow GM
    J Ren Nutr; 2024 Jul; ():. PubMed ID: 38992521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small Intestinal Phosphate Absorption: Novel Therapeutic Implications.
    Yee J; Rosenbaum D; Jacobs JW; Sprague SM
    Am J Nephrol; 2021; 52(7):522-530. PubMed ID: 34515051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
    Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease.
    Fouque D; Vervloet M; Ketteler M
    Drugs; 2018 Aug; 78(12):1171-1186. PubMed ID: 30022383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
    Chey WD; Lembo AJ; Yang Y; Rosenbaum DP
    Am J Gastroenterol; 2021 Jun; 116(6):1294-1303. PubMed ID: 33337659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal Inhibition of Sodium-Hydrogen Exchanger 3 Reduces Phosphorus Absorption and Protects against Vascular Calcification in CKD.
    Labonté ED; Carreras CW; Leadbetter MR; Kozuka K; Kohler J; Koo-McCoy S; He L; Dy E; Black D; Zhong Z; Langsetmo I; Spencer AG; Bell N; Deshpande D; Navre M; Lewis JG; Jacobs JW; Charmot D
    J Am Soc Nephrol; 2015 May; 26(5):1138-49. PubMed ID: 25404658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.
    McIntyre CW; Pai P; Warwick G; Wilkie M; Toft AJ; Hutchison AJ
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):401-9. PubMed ID: 19158369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.